Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication.

@article{May2012ConcentrationsOS,
  title={Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication.},
  author={Theodor W. May and Rainer Boor and Thomas R Mayer and Uwe J{\"u}rgens and Bernhard Rambeck and Nils Holert and Elisabeth Korn-Merker and Christian Brandt},
  journal={Therapeutic drug monitoring},
  year={2012},
  volume={34 4},
  pages={390-7}
}
BACKGROUND Stiripentol (STP) was approved as an orphan drug in 2007 in Europe as adjunctive therapy with valproic acid (VPA) and clobazam (CLB) for Dravet syndrome. Dravet syndrome is a highly pharmacoresistant form of epilepsy, which starts in early childhood. Data about STP pharmacokinetics and interactions are still limited and in part inconsistent. The aim of our study was to analyze the effect of age, gender, daily STP dose per body weight (milligrams per kilogram), VPA, CLB, and enzyme… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS